SCHEMBL20595968

SCHEMBL20595968

COc1ccc(-c2ccc(N)c3nc(Cc4nc5ccc(Cl)cc5[nH]4)cn23)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AMY1A P0DUB6 2/20 0.43
▸ EGFR P00533 2/20 0.41
▸ ERBB2 P04626 2/20 0.41
▸ F10 P00742 2/20 0.40
▸ MARS2 Q96GW9 4/20 0.40
▸ BRS3 P32247 2/20 0.39
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ RAB9A P51151 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2E1 P05181 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C8 P10632 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2B6 P20813 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419532 0.93 MARS2 (0.41) AMY1AEGFRERBB2F10MARS2
SCHEMBL20595970 0.85 MEN1 (0.39) AMY1AEGFRERBB2F10MARS2
SCHEMBL20595848 0.85 MEN1 (0.39) AMY1AEGFRERBB2F10MARS2
SCHEMBL20596612 0.84 MARS2 (0.57) F10MARS2BRS3CYP2C9
SCHEMBL30145200 0.84 MARS2 (0.57) F10MARS2BRS3CYP2C9
SCHEMBL30145089 0.82 ABL1 (0.41) AMY1AEGFRERBB2F10MARS2
SCHEMBL20595586 0.82 ABL1 (0.41) AMY1AEGFRERBB2F10MARS2
SCHEMBL23419554 0.78 MARS2 (0.38) MARS2GRIN1GRIN2BTDP1POLB
SCHEMBL23419287 0.78 MARS2 (0.40) MARS2TDP1POLBMEN1ALDH1A1
SCHEMBL23419396 0.76 NTRK1 (0.37) MARS2ALDH1A1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US claimed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US claimed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 AMY1A 2233/4885EGFR 4095/4885ERBB2 3839/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR AMY1A 3656/4885EGFR 3708/4885ERBB2 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback